Eli Lilly’s new oral GLP-1 drug, orforglipron, is shaping up to be a major development in obesity treatment, showing nearly 12% average weight loss in late-stage trials. Unlike Ozempic-style injections, it works as a simple daily pill and is now moving toward FDA review before year-end. If approved, it could reshape treatment accessibility, offering a non-injectable alternative for millions managing diabetes and obesity.